Fed. Circ. Says 'Ad Hoc' Group Can't Revive Amarin Drug IP
A Federal Circuit panel on Tuesday quickly shut down an effort by a self-described "ad hoc" group of Amarin Pharma Inc. shareholders to challenge a Nevada federal judge's decision to throw...To view the full article, register now.
Already a subscriber? Click here to view full article